PCSANM's Position on US Preventative Services Task Force Revised Guideline on Prostate Cancer Screening
However, while PCSANM is pleased with the “C” recommendation embodied in the guidelines, there are weaknesses and omissions. Why a “C” but only for men 55-69? Just because the retrospective studies to date have looked more at that age group than others ignores the fact that because prostate cancer is often slow-growing, one doesn’t see the benefits of screening sometimes for more than 10-15 years. Screening early means fewer chances of developing metastatic disease during those years, so why wait until 55 to start testing? We believe that a man’s first, baseline PSA should be around the age of 45, establishing risk and personalizing future follow up. That risk stratification is critical. PSA is just a data point; it is what you do with that information that is important.
Why does the USPSTF (that worries about over treatment if a man is diagnosed) not recommend genomic testing, MRI, liquid biopsies, and other indolent disease that might lead to active surveillance rather than treatment? Why stop testing at age 70 and classify that as a “D” recommendation? Both the American Cancer Society and National Comprehensive Cancer Network talk about testing for men with at least a ten-year life expectancy– that should be the criterion, not an arbitrary age marker. And veterans, especially those who were exposed to Agent Orange, should be included in the “higher risk” population for earlier testing, along with African-American men and men with a positive family history.
US Preventative Services Task Force (USPSTF) Revised Guideline on Prostate Cancer Screening
US Preventive Services Task Force "C" Grade for Prostate Cancer Testing
Offer or provide this service for selected patients depending on individual circumstances.
Researchers at UC San Francisco and UCLA continue to study prostate-specific membrane antigen PET imaging, or PSMA PET, to provide a more effective imaging test for men who have prostate cancer.
Steven Rowe, MD, PhD, discusses the paradigm-shifting emergence of PSMA-PET imaging in prostate cancer.
The median rPFS was 24.0 months in the apalutamide arm and 16.6 months in the placebo arm.
This study is the first to show that bacteria can produce testosterone.
In a study of men with high-risk prostate cancer as defined by National Comprehensive Cancer Network criteria, radical prostatectomy was significantly associated with a 32% reduced risk for prostate cancer mortality compared with external beam radiation therapy.
Although there was no resulting benefit to overall survival with the addition of short-term androgen deprivation to dose-escalated radiotherapy, patients with intermediate-risk prostate cancer experienced other disease benefits with this treatment approach.
After prostate cancer surgery, men can safely undergo fewer radiation treatments at higher doses, a new clinical trial shows.
The 3-year prostate cancer-specific survival decreased significantly for insured patients.
Enzalutamide plus androgen deprivation therapy improved overall survival by 34%.
Researchers from Korea reveal the key protein involved in the development of aggressive prostate cancer.